Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Drops By 79.5%

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 190,323 shares, a decline of 79.5% from the June 30th total of 929,023 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average trading volume of 8,831,855 shares, the days-to-cover ratio is presently 0.0 days.

BiomX Price Performance

BiomX stock traded down $0.01 during midday trading on Friday, hitting $0.19. 11,868,169 shares of the stock were exchanged, compared to its average volume of 5,964,777. BiomX has a fifty-two week low of $0.18 and a fifty-two week high of $13.70. The stock’s 50-day simple moving average is $0.55 and its 200 day simple moving average is $2.61.

BiomX (NYSEAMERICAN:PHGE) last issued its earnings results on Wednesday, May 20th. The company reported $7.38 EPS for the quarter. Sell-side analysts anticipate that BiomX will post -5.85 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned about 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is owned by institutional investors and hedge funds.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.